Overview

The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate

Status:
Completed
Trial end date:
2008-02-27
Target enrollment:
Participant gender:
Summary
This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy (BPH) who are over 50 years of age.
Phase:
Phase 2
Details
Lead Sponsor:
Spectrum Pharmaceuticals, Inc